Ultime notizie per Omnicell (NASDAQ:OMCL) Azioni

OMNICELL INC

Omnicell

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Omnicell Inc

In the preceding three months, 7 analysts have released ratings for Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.86, along with a high estimate of $40.00 and a low estimate of $31.00. Experiencing a 10.35% decline, the current average is now lower than the previous average price target of $40.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1748026867_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Omnicell is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omnicell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Omnicell compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Omnicell's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Omnicell's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Omnicell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Omnicell's Background</h2>
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
<h3>Omnicell: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Omnicell displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.55%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Omnicell's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.6%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Omnicell's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.56%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omnicell's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.33%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Omnicell adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OMCL

What Analysts Are Saying About Omnicell Stock

Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Overweight and raises the price target from $35 to $37.

News

Price Target

Wells Fargo Maintains Overweight on Omnicell, Raises Price Target to $37

B of A Securities analyst Allen Lutz maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Neutral and raises the price target from $30 to $34.

B of A Securities Maintains Neutral on Omnicell, Raises Price Target to $34

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday.
Shares of Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) rose sharply during Thursday&#8217;s session following better-than-expected<a href="https://www.benzinga.com/quote/AAP/earnings"> first-quarter financial results.</a>
Advance Auto Parts posted quarterly adjusted earnings per share of 22 cents loss, beating the analyst consensus estimate of 82 cents loss. Quarterly sales of $2.583 billion (down 6.8% year over year) outpaced the Street view of $2.499 billion. Comparable store sales for the first quarter 2025 decreased 0.6%.
Advance Auto Parts shares jumped 44% to $45.06 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares jumped 132% to $4.4412 after Nvidia selected the company to collaborate on 800V HVDC architecture. Additionally, Rosenblatt raised its price target on the stock from $4 to $6.</li>
<li>Domo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) rose 31.1% to $11.21 after the company reported better-than-expected first-quarter financial results and raised its FY26 guidance.</li>
<li>LiveRamp Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) rose 24.8% to $35.04 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter sales guidance above estimates.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) surged 21.1% to $72.17 following better-than-expected quarterly financial results.</li>
<li>Cantor Equity Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) gained 18.1% to $50.86.</li>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) gained 9.5% to $196.19 after the company reported better-than-expected quarterly financial results.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) rose 9.2% to $11.31. The company recently announced a secondary offering consisting of 17 million shares.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) climbed 8.8% to $3.7550.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) gained 8.7% to $29.73 after the company raised its second-quarter and FY25 adjusted EPS guidance and announced a new $75 million stock repurchase program.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) rose 7.3% to $2.1250.</li>
<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) gained 6% to $9.65 after the company announced a $150 million share repurchase program and a new CEO.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45564349/accenture-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

Trading Ideas

DOMO

LAES

NVTS

Next Technology Holding Inc. - Ordinary Shares

NXTT

RAMP

SNOW

URBN

Advance Auto Parts Posts Upbeat Results, Joins Domo, LiveRamp, Urban Outfitters And Other Big Stocks Moving Higher On Thursday

WIIM

Omnicell shares are trading higher after the company raised its Q2 and FY25 adjusted EPS guidance and announced a new $75 million stock repurchase program.

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) raises FY2025 Adj EPS guidance from $1.00-$1.65 to $1.30-$1.65 vs $1.62 analyst estimate. Affirms FY2025 sales outlook from $1.10 billion-$1.16 billion to $1.10 billion-$1.16 billion vs $1.13 billion estimate.

Guidance

Omnicell Raises FY2025 Adj EPS Guidance from $1.00-$1.65 to $1.30-$1.65 vs $1.62 Est; Affirms FY2025 Sales Guidance of $1.10B-$1.16B vs $1.13B Est

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) raises Q2 Adj EPS guidance from $0.19-$0.32 to $0.24-$0.34 vs $0.36 analyst estimate. Affirms Q2 sales outlook from $270.00 million-$280.00 million to $270.00 million-$280.00 million vs $276.59 million estimate.

Omnicell Raises Q2 Adj EPS Guidance from $0.19-$0.32 to $0.24-$0.34 vs $0.36 Est; Affirms Q2 Sales Guidance of $270.00M-$280.00M vs $276.59M Est

Omnicell, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) Board of Directors approved a new $75 million stock repurchase program (the "2025 Repurchase Program"). The 2025 Repurchase Program is in addition to the stock repurchase program approved by the Board on August 2, 2016 providing for the repurchase of up to $50.0 million of the Company's common stock (the "2016 Repurchase Program"). As of March 31, 2025, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million. Shares may be repurchased under the 2025 Repurchase Program or 2016 Repurchase Program through open market purchases, block trades, in privately negotiated transactions, accelerated or other structured stock repurchase programs, or pursuant to a Rule 10b5-1 plan. The 2025 Repurchase Program does not have an expiration date. The extent to which the Company repurchases shares of common stock, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, relevant securities laws and regulatory requirements, and other corporate considerations, as determined by the Company's management.

Buybacks

Omnicell Board Approves New $75M Stock Repurchase Program

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Mike Matson upgraded the rating for Establishment Labs Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) from Hold to Buy and announced a $48 price target. Establishment Labs shares closed at $34.96 on Tuesday. <a href="https://www.benzinga.com/quote/esta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Ashley Helgans upgraded PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Hold to Buy and raised the price target from $70 to $105. PVH shares closed at $80.50 on Tuesday. <a href="https://www.benzinga.com/quote/pvh/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Geoff Meacham upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Neutral to Buy and raised the price target from $600 to $700. Regeneron Pharmaceuticals shares closed at $574.16 on Tuesday. <a href="https://www.benzinga.com/quote/regn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stan Berenshteyn upgraded the rating for Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Equal-Weight to Overweight and raised the price target from $31 to $35. Omnicell shares closed at $28.00 on Tuesday. <a href="https://www.benzinga.com/quote/omcl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Sophie Karp upgraded the rating for Ameren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) from Sector Weight to Overweight and announced a $103 price target. Ameren shares closed at $94.32 on Tuesday. <a href="https://www.benzinga.com/quote/aee/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PVH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-1024x586.png" alt="" class="wp-image-914981" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14085608/image-162.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

ESTA

REGN

This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Wells Fargo analyst Stan Berenshteyn upgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Equal-Weight to Overweight and raises the price target from $31 to $35.

Wells Fargo Upgrades Omnicell to Overweight, Raises Price Target to $35

Ratings for Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $36.25, along with a high estimate of $40.00 and a low estimate of $31.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 21.2%. 
<img src="https://www.benzinga.com/files/images/story/2025/1746651669_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Omnicell by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Omnicell. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omnicell compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Omnicell's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Omnicell's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Omnicell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Omnicell</h2>
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
<h3>A Deep Dive into Omnicell's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Omnicell showcased positive performance, achieving a revenue growth rate of 18.56% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Omnicell's net margin excels beyond industry benchmarks, reaching 5.16%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Omnicell's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.28%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omnicell's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.72% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Omnicell's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Omnicell Stock

Benchmark analyst Bill Sutherland maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and lowers the price target from $62 to $40.

Benchmark Maintains Buy on Omnicell, Lowers Price Target to $40

Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Equal-Weight and lowers the price target from $38 to $31.

Wells Fargo Maintains Equal-Weight on Omnicell, Lowers Price Target to $31

Omnicell shares are trading lower after the company issued Q2 adjusted EPS guidance below estimates and cut its FY25 adjusted EPS guidance.

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) is looking for Q2 Adj EPS of $0.19-$0.32 vs $0.42 analyst estimate. sees sales of $270.000 million-$280.000 million vs $278.32 million analyst estimate.

Omnicell Sees Q2 Adj EPS $0.19-$0.32 vs $0.42 Est; Sees Sales $270.000M-$280.000M vs $278.32M Est

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) lowers FY2025 Adj EPS guidance from $1.65-$1.85 to $1.00-$1.65 vs $1.77 analyst estimate. Affirms FY2025 sales outlook from $1.10 billion-$1.16 billion to $1.10 billion-$1.16 billion vs $1.13 billion estimate.

Omnicell Lowers FY2025 Adj EPS Guidance from $1.65-$1.85 to $1.00-$1.65 vs $1.77 Est; Affirms FY2025 Sales Guidance of $1.10B-$1.16B vs $1.13B Est

Earnings

Earnings Beats

Omnicell Q1 Adj. EPS $0.26 Beats $0.20 Estimate, Sales $269.67M Beat $260.00M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Equal-Weight and lowers the price target from $40 to $38.

Wells Fargo Maintains Equal-Weight on Omnicell, Lowers Price Target to $38

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $46.0, along with a high estimate of $62.00 and a low estimate of $36.00. A decline of 11.96% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1742500822_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Omnicell. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Omnicell. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omnicell compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Omnicell's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Omnicell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Omnicell's Background</h2>
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
<h3>Unraveling the Financial Story of Omnicell</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Omnicell's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.56% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.16%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Omnicell's ROE stands out, surpassing industry averages. With an impressive ROE of 1.28%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.72%, the company showcases effective utilization of assets.
Debt Management: Omnicell's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Press Releases

Omnicell to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

Omnicell Announces Chief Financial Officer Transition

Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer

Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

Omnicell Announces First Quarter 2025 Results

Omnicell Opens New Innovation Lab in Austin, Texas

Omnicell Announces New Products for Perioperative and Clinic Settings

Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

Comments

Omnicell

Notizie

Ultime notizie per Omnicell (NASDAQ:OMCL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO